- Home
- PMNT vs NERV Comparison
PMNT vs NERV Comparison
Compare PMNT & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMNT
- NERV
- Stock Information
- Founded
- PMNT 1984
- NERV 2007
- Country
- PMNT United Kingdom
- NERV United States
- Employees
- PMNT N/A
- NERV N/A
- Industry
- PMNT
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- PMNT
- NERV Health Care
- Exchange
- PMNT NYSE
- NERV Nasdaq
- Market Cap
- PMNT 19.1M
- NERV 16.0M
- IPO Year
- PMNT 2024
- NERV 2014
- Fundamental
- Price
- PMNT $1.13
- NERV $2.23
- Analyst Decision
- PMNT Strong Buy
- NERV Hold
- Analyst Count
- PMNT 1
- NERV 1
- Target Price
- PMNT $6.00
- NERV $5.00
- AVG Volume (30 Days)
- PMNT 41.9K
- NERV 37.0K
- Earning Date
- PMNT 11-14-2024
- NERV 02-20-2025
- Dividend Yield
- PMNT N/A
- NERV N/A
- EPS Growth
- PMNT N/A
- NERV N/A
- EPS
- PMNT N/A
- NERV N/A
- Revenue
- PMNT $22,375,000.00
- NERV N/A
- Revenue This Year
- PMNT $3.91
- NERV N/A
- Revenue Next Year
- PMNT $29.32
- NERV N/A
- P/E Ratio
- PMNT N/A
- NERV N/A
- Revenue Growth
- PMNT N/A
- NERV N/A
- 52 Week Low
- PMNT $0.70
- NERV $2.06
- 52 Week High
- PMNT $6.05
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- PMNT N/A
- NERV 50.40
- Support Level
- PMNT N/A
- NERV $2.07
- Resistance Level
- PMNT N/A
- NERV $2.39
- Average True Range (ATR)
- PMNT 0.00
- NERV 0.12
- MACD
- PMNT 0.00
- NERV -0.01
- Stochastic Oscillator
- PMNT 0.00
- NERV 48.48
About PMNT PERFECT MOMENT LTD
Perfect Moment Ltd is a company which is a luxury lifestyle brand that combines fashion and technical performance for its ranges of skiwear, outerwear, swimwear, and activewear. It operates at the intersection of luxury fashion and multi-channel commerce. Although the Company is organized fundamentally as one business segment which is product sales, the Company's revenues are primarily split between three geographic areas which are the U. S., Europe, and the UK.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.